⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL296265 | 0.58 | — | — | |
| SCHEMBL18436443 | 0.57 | — | — | |
| SCHEMBL27683385 | 0.56 | — | — | |
| SCHEMBL13721028 | 0.56 | — | — | |
| SCHEMBL2045252 | 0.55 | — | — | |
| SCHEMBL2043629 | 0.51 | — | — | |
| SCHEMBL5161070 | 0.50 | — | — | |
| SCHEMBL10524285 | 0.48 | — | — | |
| SCHEMBL14157909 | 0.48 | — | — | |
| SCHEMBL23706613 | 0.43 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10174077-B2 | Method of inhibiting activity of cell surface fibroblast activation protein alpha | THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA (US) | 2019-01-08 | — | — | US | disclosed |
| US-10155789-B2 | Substrates and inhibitors of prolyl oligopeptidase and methods of use thereof | THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA (US) | 2018-12-18 | — | — | US | disclosed |
| US-20170260231-A1 | Substrates and Inhibitors of Prolyl Oligopeptidase and Methods of Use Thereof | UNIV OKLAHOMA (US) | 2017-09-14 | — | — | US | disclosed |
| US-9688722-B2 | Substrates and inhibitors of prolyl oligopeptidase and methods of use | THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA (US) | 2017-06-27 | — | — | US | disclosed |
| US-20170066800-A1 | Substrates and Inhibitors of Antiplasmin Cleaving Enzyme and Fibroblast Activation Protein and Methods of Use | UNIV OKLAHOMA (US) | 2017-03-09 | — | — | US | disclosed |
| US-9527884-B2 | Substrates and inhibitors of antiplasmin cleaving enzyme and fibroblast activation protein and methods of use | THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA (US) | 2016-12-27 | — | — | US | disclosed |
| US-20150141660-A1 | Substrates and Inhibitors of Antiplasmin Cleaving Enzyme and Fibroblast Activation Protein and Methods of Use | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-05-21 | — | — | US | disclosed |
| US-20150119330-A1 | SUBSTRATES AND INHIBITORS OF PROLYL OLIGOPEPTIDASE AND FIBROBLAST ACTIVATION PROTEIN AND METHODS OF USE | THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA | 2015-04-30 | — | — | US | disclosed |
| EP-2844246-A1 | SUBSTRATES AND INHIBITORS OF PROLYL OLIGOPEPTIDASE AND FIBROBLAST ACTIVATION PROTEIN AND METHODS OF USE | The Board of Regents of the University of Oklahoma (US) | 2015-03-11 | — | — | EP | disclosed |
| US-8933201-B2 | Substrates and inhibitors of antiplasmin cleaving enzyme and fibroblast activation protein and methods of use | THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA (US) | 2015-01-13 | — | — | US | disclosed |
| US-20040077601-A1 | Methods and compositions relating to isoleucine boroproline compounds | POINT THERAPEUTICS, INC. | 2004-04-22 | — | — | US | disclosed |
| WO-2004004661-A2 | BOROPROLINE COMPOUND COMBINATION THERAPY | POINT THERAPEUTICS, INC. (US) | 2004-01-15 | — | — | WO | disclosed |
| WO-2004004658-A2 | METHODS AND COMPOSITIONS RELATING TO ISOLEUCINE BOROPROLINE COMPOUNDS | POINT THERAPEUTICS, INC. (US) | 2004-01-15 | — | — | WO | disclosed |
| US-20030158114-A1 | Anti-tumor agents | POINT THERAPEUTICS, INC. | 2003-08-21 | — | — | US | disclosed |
| US-20020123461-A1 | Enhancement of GLP-2 activity | 1149336 ONTARIO INC. | 2002-09-05 | — | — | US | disclosed |
| WO-2002066062-A2 | ENHANCEMENT OF GLP-2 ACTIVITY | DRUCKER DANIEL J (CA) | 2002-08-29 | — | — | WO | disclosed |
| EP-1187619-A1 | ANTI-TUMOR AGENTS COMPRISING BOROPROLINE COMPOUNDS | Point Therapeutics, Inc. (US) | 2002-03-20 | — | — | EP | disclosed |
| WO-2000071135-A1 | ANTI-TUMOR COMPRISING BOROPROLINE COMPOUNDS | POINT THERAPEUTICS, INC. (US) | 2000-11-30 | — | — | WO | disclosed |
| US-6110949-A | A SERINE PROTEASE INHIBITOR TREATING NON-INSULIN-DEPENDENT DIABETES MELLITUS | NOVARTIS AG (CH) | 2000-08-29 | — | — | US | disclosed |
| US-6107317-A | ANTIDIABETIC AGENTS | NOVARTIS AG (CH) | 2000-08-22 | — | — | US | disclosed |